U.S. FDA Approves Prevnar 20, Pfizer ’s 20-Valent Pneumococcal Conjugate Vaccine for Infants and Children

NEW YORK--(BUSINESS WIRE) April 27, 2023 -- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Prevnar 20®(20-valent Pneumococcal Conjugate Vaccine) for the prevention of invasive pneumococcal...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news